Quarterly ResultApr 30, 2026, 07:12 AM
PHAT Q1 Net Loss $(30.4)M, Revenue +104%; Debt Refinanced
AI Summary
Phathom Pharmaceuticals reported a significant improvement in its net loss for Q1 2026, driven by a substantial increase in product revenue and reduced operating expenses. The company also completed a major debt refinancing, securing a new $175 million term loan and extending its maturity date, alongside raising $122 million from a public offering. Management believes it has sufficient working capital for the next twelve months.
Key Highlights
- Q1 2026 net loss improved to $(30.4)M from $(94.3)M YoY.
- Product revenue surged 104.4% to $58.3M in Q1 2026.
- Operating expenses decreased 40.4% to $61.8M in Q1 2026.
- Secured a new $175M term loan, repaying existing debt.
- Extended debt maturity to Feb 2029 and interest-only period to Dec 2027.
- Raised $122M net proceeds from an underwritten public offering.
- Net cash used in operating activities reduced to $(15.6)M from $(84.9)M YoY.
- Cash and cash equivalents increased to $180.9M as of March 31, 2026.